Potential effects of lignan-enriched flaxseed powder on bodyweight, visceral fat, lipid profile, and blood pressure in rats

Hill, 1998, Environmental contributions to the obesity epidemic, Science, 280, 1371, 10.1126/science.280.5368.1371 Schrauwen, 2000, The role of high-fat diets and physical activity in the regulation of body weight, Br J Nutr, 84, 417, 10.1017/S0007114500001720 Reilly, 2008, Objective measurement of physical activity and sedentary behaviour: review with new data, Arch Dis Child, 93, 614, 10.1136/adc.2007.133272 Chaput, 2009, Obesity and physical inactivity: the relevance of reconsidering the notion of sedentariness, Obes Facts, 2, 249, 10.1159/000227287 Hamilton, 2007, Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease, Diabetes, 56, 2655, 10.2337/db07-0882 Misra, 2010, Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils, J Am Coll Nutr, 29, 289S, 10.1080/07315724.2010.10719844 Ritchie, 2007, The link between abdominal obesity, metabolic syndrome and cardiovascular disease, Nutr Metab Cardiovasc Dis, 17, 319, 10.1016/j.numecd.2006.07.005 Tailor, 2010, An update on the prevalence of the metabolic syndrome in children and adolescents, Int J Pediatr Obes, 5, 202, 10.3109/17477160903281079 Gallagher, 2010, Insulin resistance in obesity as the underlying cause for the metabolic syndrome, Mt Sinai J Med, 77, 511, 10.1002/msj.20212 Natali, 2009, Metabolic syndrome: at the crossroads of cardiorenal risk, J Nephrol, 22, 29 Horita, 2011, Insulin resistance, obesity, hypertension, and renal sodium transport, Int J Hypertens, 391762 Wahba, 2007, Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease, Clin J Am Soc Nephrol, 2, 550, 10.2215/CJN.04071206 Guize, 2008, Recent advances in metabolic syndrome and cardiovascular disease, Arch Cardiovasc Dis, 101, 577, 10.1016/j.acvd.2008.06.011 Després, 2008, Abdominal obesity: the cholesterol of the 21st century?, Can J Cardiol, 24, 7D, 10.1016/S0828-282X(08)71043-2 Bakris, 2007, Current perspectives on hypertension and metabolic syndrome, J Manag Care Pharm, 13, S3, 10.18553/jmcp.2007.13.s5.3 Santos, 2010, Edible plants, their secondary metabolites and antiobesogenic potential, Recent Pat Food Nutr Agric, 2, 195, 10.2174/1876142911002030195 Singh, 2011, Flaxseed: a potential source of food, feed and fiber, Crit Rev Food Sci Nutr, 51, 210, 10.1080/10408390903537241 Rhee, 2011, Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design, Nutr J, 10, 44, 10.1186/1475-2891-10-44 Adolphe, 2010, Health effects with consumption of the flax lignan secoisolariciresinol diglucoside, Br J Nutr, 103, 929, 10.1017/S0007114509992753 Prasad, 2009, Flaxseed and cardiovascular health, J Cardiovasc Pharmacol, 54, 369, 10.1097/FJC.0b013e3181af04e5 Thakur, 2009, Effect of flaxseed gum on reduction of blood glucose and cholesterol in type 2 diabetic patients, Int J Food Sci Nutr, 22, 1 Fukumitsu, 2010, Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men, Nutr Res, 30, 441, 10.1016/j.nutres.2010.06.004 Rodriguez-Leyva, 2010, The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid, Can J Cardiol, 26, 489, 10.1016/S0828-282X(10)70455-4 Hu, 2007, Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro, Food Chem Toxicol, 45, 2219, 10.1016/j.fct.2007.05.017 Felmlee, 2009, Effects of the flaxseed lignans secoisolariciresinol diglucoside and its aglycone on serum and hepatic lipids in hyperlipidaemic rats, Br J Nutr, 102, 361, 10.1017/S0007114508207488 Zhang, 2008, Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia, J Med Food, 11, 207, 10.1089/jmf.2007.602 Penumathsa, 2007, Secoisolariciresinol diglucoside: relevance to angiogenesis and cardioprotection against ischemia–reperfusion injury, J Pharmacol Exp Ther, 320, 951, 10.1124/jpet.106.114165 Deng, 2010, Adipokines as novel biomarkers and regulators of the metabolic syndrome, Ann N Y Acad Sci, 1212, E1, 10.1111/j.1749-6632.2010.05875.x Suganami, 2010, Adipose tissue macrophages: their role in adipose tissue remodeling, J Leukoc Biol, 88, 33, 10.1189/jlb.0210072 Cui, 2011, The role of adiponectin in metabolic and vascular disease, Clin Nephrol, 75, 26 Onat, 2011, Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk, Metabolism, 60, 499, 10.1016/j.metabol.2010.04.018 Nakajima, 2010, Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome, Curr Clin Pharmacol, 5, 133, 10.2174/157488410791110760 Galic, 2010, Adipose tissue as an endocrine organ, Mol Cell Endocrinol, 316, 129, 10.1016/j.mce.2009.08.018 Rasouli, 2008, Adipocytokines and the metabolic complications of obesity, J Clin Endocrinol Metab, 93, S64, 10.1210/jc.2008-1613 Lumeng, 2011, Inflammatory links between obesity and metabolic disease, J Clin Invest, 121, 2111, 10.1172/JCI57132 Villanueva, 2008, Leptin receptor signaling and the regulation of mammalian physiology, Int J Obes (Lond), 7, S8, 10.1038/ijo.2008.232 de Luis, 2009, Leptin and obesity, Minerva Med, 100, 229 Maury, 2010, Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome, Mol Cell Endocrinol, 314, 1, 10.1016/j.mce.2009.07.031 Cawthorn, 2008, TNF-alpha and adipocyte biology, FEBS Lett, 582, 117, 10.1016/j.febslet.2007.11.051 Warne, 2003, Tumour necrosis factor alpha: a key regulator of adipose tissue mass, J Endocrinol, 177, 351, 10.1677/joe.0.1770351 Gurevich-Panigrahi, 2009, Obesity: pathophysiology and clinical management, Curr Med Chem, 16, 506, 10.2174/092986709787315568 Forsythe, 2008, Obesity and inflammation: the effects of weight loss, Nutr Res Rev, 21, 117, 10.1017/S0954422408138732 Hajer, 2008, Adipose tissue dysfunction in obesity, diabetes, and vascular diseases, Eur Heart J, 29, 2959, 10.1093/eurheartj/ehn387 Klempel, 2011, Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans, Nutr Rev, 69, 145, 10.1111/j.1753-4887.2011.00373.x Varady, 2009, Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women, Metabolism, 58, 1096, 10.1016/j.metabol.2009.04.010 Romeo, 2011, Changes in cardiometabolic risk factors, appetite-controlling hormones and cytokines after a treatment program in overweight adolescents, Pediatr Diabetes, 12, 372, 10.1111/j.1399-5448.2010.00753.x Ibrahim, 2010, Weight loss: a neglected intervention in the management of chronic kidney disease, Curr Opin Nephrol Hypertens, 19, 534, 10.1097/MNH.0b013e32833f13de Wallace, 2003, Exercise in hypertension, a clinical review, Sports Med, 33, 585, 10.2165/00007256-200333080-00004 Lambert, 2010, Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications, Pharmacol Ther, 126, 159, 10.1016/j.pharmthera.2010.02.002 Niswender, 2010, Diabetes and obesity: therapeutic targeting and risk reduction — a complex interplay, Diabetes Obes Metab, 12, 267, 10.1111/j.1463-1326.2009.01175.x